Do analysts rate ERNA or VBIO?

Ernexa Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 602.58%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ERNA or VBIO more profitable?

Valion Bio, Inc. Common Stock's return on equity of -138.10% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics N/A -305.93% -169.86% Valion Bio, Inc. Common Stock N/A -138.10% -63.67%

Does the media refer more to ERNA or VBIO?

In the previous week, Valion Bio, Inc. Common Stock had 8 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 11 mentions for Valion Bio, Inc. Common Stock and 3 mentions for Ernexa Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.51 beat Valion Bio, Inc. Common Stock's score of 0.16 indicating that Ernexa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ernexa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Valion Bio, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer HCWB or VBIO?

HCW Biologics currently has a consensus target price of $30.00, suggesting a potential upside of 1,019.40%. Given HCW Biologics' stronger consensus rating and higher possible upside, equities analysts clearly believe HCW Biologics is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor HCWB or VBIO?

In the previous week, Valion Bio, Inc. Common Stock had 7 more articles in the media than HCW Biologics. MarketBeat recorded 11 mentions for Valion Bio, Inc. Common Stock and 4 mentions for HCW Biologics. HCW Biologics' average media sentiment score of 0.58 beat Valion Bio, Inc. Common Stock's score of 0.16 indicating that HCW Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HCW Biologics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valion Bio, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CRIS or VBIO?

Curis presently has a consensus price target of $43.00, suggesting a potential upside of 2,288.89%. Given Curis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Curis is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curis 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor CRIS or VBIO?

In the previous week, Valion Bio, Inc. Common Stock had 4 more articles in the media than Curis. MarketBeat recorded 11 mentions for Valion Bio, Inc. Common Stock and 7 mentions for Curis. Valion Bio, Inc. Common Stock's average media sentiment score of 0.16 beat Curis' score of 0.13 indicating that Valion Bio, Inc. Common Stock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Curis 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Valion Bio, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend MBIO or VBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MBIO or VBIO more profitable?

Mustang Bio's return on equity of -34.23% beat Valion Bio, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Mustang Bio N/A -34.23% -17.55% Valion Bio, Inc. Common Stock N/A -138.10% -63.67%

Do analysts rate VBIO or CLGN?

CollPlant Biotechnologies has a consensus price target of $11.50, indicating a potential upside of 3,388.02%. Given CollPlant Biotechnologies' stronger consensus rating and higher probable upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CollPlant Biotechnologies 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Valion Bio, Inc. Common Stock (VBIO) Competitors

$0.19 +0.02 (+11.59%)

As of 04:00 PM Eastern

Compare

VBIO vs. ERNA, HCWB, CRIS, MBIO, and CLGN

Should you buy Valion Bio, Inc. Common Stock stock or one of its competitors? Valion Bio, Inc. Common Stock's main competitors and comparable companies include Ernexa Therapeutics (ERNA), HCW Biologics (HCWB), Curis (CRIS), Mustang Bio (MBIO), and CollPlant Biotechnologies (CLGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Valion Bio, Inc. Common Stock compare to Ernexa Therapeutics?

Ernexa Therapeutics (NASDAQ:ERNA) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Valion Bio, Inc. Common Stock has higher revenue and earnings than Ernexa Therapeutics. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580K	12.00	-$14.08M	-$14.35	N/A
Valion Bio, Inc. Common Stock	$780K	1.01	-$8.88M	-$6.68	N/A

In the previous week, Valion Bio, Inc. Common Stock had 8 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 11 mentions for Valion Bio, Inc. Common Stock and 3 mentions for Ernexa Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.51 beat Valion Bio, Inc. Common Stock's score of 0.16 indicating that Ernexa Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ernexa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Valion Bio, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ernexa Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 602.58%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Ernexa Therapeutics has a beta of 2.57, suggesting that its share price is 157% more volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market.

Valion Bio, Inc. Common Stock's return on equity of -138.10% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-305.93%	-169.86%
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%

70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. 0.5% of Ernexa Therapeutics shares are owned by company insiders. Comparatively, 2.5% of Valion Bio, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Valion Bio, Inc. Common Stock beats Ernexa Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to HCW Biologics?

HCW Biologics (NASDAQ:HCWB) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

3.0% of HCW Biologics shares are owned by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. 9.1% of HCW Biologics shares are owned by insiders. Comparatively, 2.5% of Valion Bio, Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

HCW Biologics has higher earnings, but lower revenue than Valion Bio, Inc. Common Stock. HCW Biologics is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	85.76	-$7.96M	-$56.75	N/A
Valion Bio, Inc. Common Stock	$780K	1.01	-$8.88M	-$6.68	N/A

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Valion Bio, Inc. Common Stock's return on equity of -138.10% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-34.73%	-486.87%	-29.19%
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%

HCW Biologics currently has a consensus target price of $30.00, suggesting a potential upside of 1,019.40%. Given HCW Biologics' stronger consensus rating and higher possible upside, equities analysts clearly believe HCW Biologics is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

HCW Biologics has a beta of 2.32, meaning that its share price is 132% more volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.85, meaning that its share price is 85% more volatile than the broader market.

In the previous week, Valion Bio, Inc. Common Stock had 7 more articles in the media than HCW Biologics. MarketBeat recorded 11 mentions for Valion Bio, Inc. Common Stock and 4 mentions for HCW Biologics. HCW Biologics' average media sentiment score of 0.58 beat Valion Bio, Inc. Common Stock's score of 0.16 indicating that HCW Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HCW Biologics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valion Bio, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

HCW Biologics beats Valion Bio, Inc. Common Stock on 9 of the 16 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to Curis?

Curis (NASDAQ:CRIS) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Curis has a beta of 3.13, suggesting that its stock price is 213% more volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.85, suggesting that its stock price is 85% more volatile than the broader market.

30.0% of Curis shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 5.8% of Curis shares are held by insiders. Comparatively, 2.5% of Valion Bio, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to Curis' net margin of -80.29%. Curis' return on equity of 0.00% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	N/A	-181.57%
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%

Curis has higher revenue and earnings than Valion Bio, Inc. Common Stock. Curis is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$9.44M	0.40	-$7.58M	-$23.80	N/A
Valion Bio, Inc. Common Stock	$780K	1.01	-$8.88M	-$6.68	N/A

In the previous week, Valion Bio, Inc. Common Stock had 4 more articles in the media than Curis. MarketBeat recorded 11 mentions for Valion Bio, Inc. Common Stock and 7 mentions for Curis. Valion Bio, Inc. Common Stock's average media sentiment score of 0.16 beat Curis' score of 0.13 indicating that Valion Bio, Inc. Common Stock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Curis	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Valion Bio, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Curis presently has a consensus price target of $43.00, suggesting a potential upside of 2,288.89%. Given Curis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Curis is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Curis beats Valion Bio, Inc. Common Stock on 9 of the 16 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to Mustang Bio?

Mustang Bio (NASDAQ:MBIO) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

10.0% of Mustang Bio shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 4.0% of Mustang Bio shares are held by company insiders. Comparatively, 2.5% of Valion Bio, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Mustang Bio's return on equity of -34.23% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mustang Bio	N/A	-34.23%	-17.55%
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%

Mustang Bio has higher earnings, but lower revenue than Valion Bio, Inc. Common Stock. Mustang Bio is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mustang Bio	N/A	N/A	-$1.92M	-$0.45	N/A
Valion Bio, Inc. Common Stock	$780K	1.01	-$8.88M	-$6.68	N/A

In the previous week, Valion Bio, Inc. Common Stock had 10 more articles in the media than Mustang Bio. MarketBeat recorded 11 mentions for Valion Bio, Inc. Common Stock and 1 mentions for Mustang Bio. Mustang Bio's average media sentiment score of 1.87 beat Valion Bio, Inc. Common Stock's score of 0.16 indicating that Mustang Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Mustang Bio	Very Positive
Valion Bio, Inc. Common Stock	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mustang Bio has a beta of 2.06, suggesting that its stock price is 106% more volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.85, suggesting that its stock price is 85% more volatile than the broader market.

Summary

Mustang Bio beats Valion Bio, Inc. Common Stock on 8 of the 11 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to CollPlant Biotechnologies?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

In the previous week, Valion Bio, Inc. Common Stock had 9 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 11 mentions for Valion Bio, Inc. Common Stock and 2 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.94 beat Valion Bio, Inc. Common Stock's score of 0.16 indicating that CollPlant Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valion Bio, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CollPlant Biotechnologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 2.5% of Valion Bio, Inc. Common Stock shares are owned by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valion Bio, Inc. Common Stock has a beta of 1.85, indicating that its stock price is 85% more volatile than the broader market. Comparatively, CollPlant Biotechnologies has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market.

CollPlant Biotechnologies has a consensus price target of $11.50, indicating a potential upside of 3,388.02%. Given CollPlant Biotechnologies' stronger consensus rating and higher probable upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Valion Bio, Inc. Common Stock has higher earnings, but lower revenue than CollPlant Biotechnologies. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	$780K	1.01	-$8.88M	-$6.68	N/A
CollPlant Biotechnologies	$2.37M	2.01	-$11.49M	-$1.45	N/A

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -683.68%. Valion Bio, Inc. Common Stock's return on equity of -138.10% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%

Summary

CollPlant Biotechnologies beats Valion Bio, Inc. Common Stock on 9 of the 16 factors compared between the two stocks.

Get Valion Bio, Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VBIO vs. The Competition

Export

Metric	Valion Bio, Inc. Common Stock	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$710K	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-0.03	6.29	211.09	21.74
Price / Sales	1.01	1,295.89	602.98	92.99
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	0.03	16.78	12.91	6.24
Net Income	-$8.88M	-$13.32M	$3.45B	$347.60M
7 Day Performance	-33.22%	1.74%	1.12%	1.07%
1 Month Performance	-59.38%	1.60%	1.79%	1.03%
1 Year Performance	-94.55%	56.43%	67.69%	20.77%

Valion Bio, Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VBIO Valion Bio, Inc. Common Stock	0.457 of 5 stars	$0.19 +11.6%	N/A	-95.1%	$710K	$780K	N/A	10	News Coverage Earnings Report Gap Down High Trading Volume
ERNA Ernexa Therapeutics	2.8895 of 5 stars	$4.42 +0.7%	$30.00 +578.7%	-89.4%	$5.12M	$580K	N/A	10	Gap Up
HCWB HCW Biologics	3.9221 of 5 stars	$3.14 -0.9%	$30.00 +855.4%	-89.2%	$5.06M	$50K	N/A	40	News Coverage Earnings Report
CRIS Curis	2.35 of 5 stars	$1.67 -27.7%	$43.00 +2,474.9%	-94.6%	$4.83M	$9.44M	N/A	60	News Coverage Earnings Report Analyst Downgrade Gap Down High Trading Volume
MBIO Mustang Bio	1.3365 of 5 stars	$0.61 -0.4%	N/A	-68.2%	$4.61M	N/A	N/A	100	Positive News Upcoming Earnings High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VBIO) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Valion Bio, Inc. Common Stock (VBIO) Competitors

VBIO vs. ERNA, HCWB, CRIS, MBIO, and CLGN

How does Valion Bio, Inc. Common Stock compare to Ernexa Therapeutics?

Summary

How does Valion Bio, Inc. Common Stock compare to HCW Biologics?

Summary

How does Valion Bio, Inc. Common Stock compare to Curis?

Summary

How does Valion Bio, Inc. Common Stock compare to Mustang Bio?

Summary

How does Valion Bio, Inc. Common Stock compare to CollPlant Biotechnologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIO vs. The Competition

Valion Bio, Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Valion Bio, Inc. Common Stock (VBIO) Competitors

VBIO vs. ERNA, HCWB, CRIS, MBIO, and CLGN

How does Valion Bio, Inc. Common Stock compare to Ernexa Therapeutics?

Which has preferable earnings & valuation, ERNA or VBIO?

Does the media refer more to ERNA or VBIO?

Do analysts rate ERNA or VBIO?

Which has more volatility and risk, ERNA or VBIO?

Is ERNA or VBIO more profitable?

Do insiders & institutionals have more ownership in ERNA or VBIO?

Summary

How does Valion Bio, Inc. Common Stock compare to HCW Biologics?

Do insiders and institutionals hold more shares of HCWB or VBIO?

Which has stronger valuation & earnings, HCWB or VBIO?

Is HCWB or VBIO more profitable?

Do analysts prefer HCWB or VBIO?

Which has more volatility and risk, HCWB or VBIO?

Does the media favor HCWB or VBIO?

Summary

How does Valion Bio, Inc. Common Stock compare to Curis?

Which has more volatility & risk, CRIS or VBIO?

Do institutionals and insiders hold more shares of CRIS or VBIO?

Is CRIS or VBIO more profitable?

Which has preferable valuation & earnings, CRIS or VBIO?

Does the media favor CRIS or VBIO?

Do analysts prefer CRIS or VBIO?

Summary

How does Valion Bio, Inc. Common Stock compare to Mustang Bio?

Do institutionals & insiders have more ownership in MBIO or VBIO?

Is MBIO or VBIO more profitable?

Which has higher valuation and earnings, MBIO or VBIO?

Does the media refer more to MBIO or VBIO?

Do analysts recommend MBIO or VBIO?

Which has more volatility & risk, MBIO or VBIO?

Summary

How does Valion Bio, Inc. Common Stock compare to CollPlant Biotechnologies?

Does the media prefer VBIO or CLGN?

Do insiders & institutionals have more ownership in VBIO or CLGN?

Which has more risk & volatility, VBIO or CLGN?

Do analysts rate VBIO or CLGN?

Which has stronger earnings and valuation, VBIO or CLGN?

Is VBIO or CLGN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIO vs. The Competition

Valion Bio, Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools